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Background: Exercise has favorable effects on biomarkers associated with a lower risk of breast cancer, however
it is unclear if higher doses of exercise provide additional effects. No clinical trial has systematically examined how
different exercise volumes influence the mechanisms underlying breast cancer etiology. The Breast Cancer and
Exercise Trial in Alberta (BETA) - a follow-up study to the Alberta Physical Activity and Breast Cancer Prevention
(ALPHA) Trial - is examining how a one-year, high versus moderate volume aerobic exercise intervention influences
several biomechanisms hypothesized to influence breast cancer risk in a group of postmenopausal women. Secondary
aims are to compare intervention effects on psychosocial and quality of life outcomes as well as understand exercise
adherence at 12 and 24 months, and maintenance of all study outcomes at 24 months.
Methods/Design: The BETA Trial is a two-center, two-armed randomized controlled exercise intervention trial
conducted in 400 previously inactive, postmenopausal women aged 50–74 years, in Alberta, Canada. Participants
were randomly assigned to a one-year aerobic exercise intervention of either high volume (300 minutes/week) or
moderate volume (150 minutes/week). Blood draws and accelerometry were performed at baseline, six and
12 months. Baseline and 12-month measurements were taken of adiposity (including dual energy X-ray absorptiometry
and computed tomography scans), physical fitness, dietary intake, self-reported physical activity and sedentary behavior,
quality of life, perceived stress, happiness, sleep, and determinants of exercise adherence. Exercise maintenance was
assessed and all study measurements were repeated at 24 months. Blood will be analyzed for endogenous estrogens,
insulin resistance indicators, and inflammatory markers.
Discussion: The BETA Trial will compare the impact of a high versus moderate volume of aerobic exercise on a variety
of biological, physiological, and psychological outcomes of relevance to postmenopausal women. A tightly controlled
exercise intervention and objective outcome measurements are methodological strengths. The BETA Trial will inform
future prevention initiatives by assessing adherence to a high volume of exercise over 12 months by postmenopausal
women, and the ability of these women to maintain activity over the longer-term. The ultimate objective is to inform
public health guidelines for reducing breast cancer risk through physical activity.
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Breast cancer is a significant health risk for women in
North America, particularly after age 50. Canadian women
have a 1-in-9 lifetime probability of developing breast can-
cer [1] and in the U.S. this estimate is 1-in-8 [2]. Inadequate
physical activity is a probable risk factor for postmeno-
pausal breast cancer [3] and is one of the few known risk
factors that is modifiable. Recent estimates suggest that
physical inactivity accounts for nearly 20% of all postmen-
opausal breast cancer cases in Canada [4] and about 10%
of all breast cancer cases internationally [5]. On average
women with the highest versus the lowest activity levels
experience a 10-25% lower risk of breast cancer [6,7]. In
postmenopausal women the hypothesized biologic mecha-
nisms underlying the association are not well understood
but might involve multiple, interrelated pathways relating
to sex hormones, insulin resistance, low-grade chronic in-
flammation, adipokines and other factors [8] with body fat
partially mediating some of these effects [9-12]. As the
preventive effects of physical activity become increasingly
clear, questions remain surrounding the optimal dose of
activity that is required to reduce postmenopausal breast
cancer risk.
In North America and worldwide, guidelines on phys-
ical activity and cancer prevention vary between public
health agencies. With respect to aerobic activity, recom-
mendations for adults include:
 a minimum of 150 minutes/week of moderate- or
75 minutes of vigorous-intensity activity [13,14];
 150 minutes/week of moderate-vigorous activity
[15,16]; and
 210 minutes/week of moderate activity [3].
As fitness levels improve, some agencies further recommend:
 300 [13,14] or 420 [3] minutes/week of at least
moderate activity; or
 150 [13] or 210 [3] minutes/week of vigorous
activity.
In addition, muscle-strengthening exercise [13,15] and
limiting sedentary behavior [3,14] are advised. However
it remains unproven - and even doubtful [17] - that all
of these current recommendations are sufficient for low-
ering postmenopausal breast cancer risk. These guide-
lines were based partly on findings from observational
studies of physical activity and overall cancer risk. With
respect to breast cancer risk specifically, inverse dose–
response relations with minutes/week of physical activity
have been shown in pooled [18] and meta-analyses [7] of
case–control and/or cohort studies. However, observa-
tional studies alone cannot inform public health guide-
lines due to their inherent limitations (e.g., inconsistentdefinitions of physical activity, physical activity measure-
ment error, and possible confounding by other factors).
A more definitive understanding of the dose–response
relation can be gained using a randomized controlled
trial (RCT) study design.
In the Alberta Physical Activity and Breast Cancer
Prevention (ALPHA) Trial [19], we examined how a 12-
month aerobic exercise prescription, compared with a
usual inactive lifestyle, influenced hypothesized biologic
mechanisms for breast cancer risk in 320 postmenopausal
women in Alberta, Canada. The exercise group was
prescribed 225 minutes/week of moderate-vigorous phys-
ical activity, five days a week, with at least half of each work-
out reaching 70-80% heart rate reserve. Among women
assigned to the exercise arm (n = 160), we observed a strong
effect of exercise on the main proposed biomarkers of
interest that included an effect on endogenous estrogens,
insulin resistance, inflammation and body composition
[19-22]. In addition, we observed favorable dose–response
relations across subgroups of exercise adherence (minutes/
week) with respect to 12-month changes in body weight,
total body fat, and intra-abdominal fat area [20], circulating
free estradiol and sex hormone-binding globulin (SHBG)
levels [19], insulin and the homeostasis model assessment
of insulin resistance (HOMA-IR), leptin, adiponectin:leptin
[21] and high sensitivity C-reactive protein (CRP), with
the strongest changes occurring when exercise exceeded
150 or 225 minutes/week. Dose–response relations were
not found for androgens [19], tumor necrosis factor-alpha
(TNF-α) or interleukin-6 (IL-6) [22]. Furthermore, greater
improvements in quality of life variables were observed
with exercise duration over 150 minutes/week (p-trend <
0.05 for seven of eight quality of life variables) [23]. Two
comparable trials in postmenopausal women [10,24] ob-
served similar effects of an exercise intervention on
hypothesized breast cancer biomarkers as well as some
suggestion of a dose–response effect with stronger im-
provements in some biomarkers when exercise exceeded
195 minutes/week [24-26] or 130 minutes/week [12,27]
but not with others [10,11,28,29]. Yet all of these findings
are limited for informing breast cancer prevention guide-
lines due to the non-randomized, exploratory nature of
the analyses (participants within the exercise arm self-
selected to adherence levels) and lower statistical power
for detecting significant differences in biomarker changes
across strata of exercise adherence.
Other RCTs have been designed and statistically pow-
ered to compare changes across increasing durations of
exercise [30-38] such as the Dose–Response to Exercise
in Women (DREW) trial in over 450 postmenopausal
women [33,39-41]. The DREW trial showed favourable
dose–response trends across moderate-intensity (50%
VO2max) exercise durations of approximately 75, 140,
and 190 minutes/week and quality of life variables [41]
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cumference [40] or CRP levels [39]. While studies like the
DREW trial provide more convincing evidence of dose–
response relations, the exercise prescriptions did not target
primary cancer prevention, few breast cancer biomarkers
were examined, and only some of the trials [30,31,33,34]
studied postmenopausal women exclusively.
Evolving from the ALPHA Trial, the Breast Cancer and
Exercise Trial in Alberta (BETA) Trial was conducted
in Alberta, Canada between 2010 and 2014. The primary
objective was to compare the effects of a high versus
moderate volume of aerobic exercise on proposed bio-
logic intermediate endpoints for breast cancer in previ-
ously inactive, postmenopausal women. We hypothesized
that 300 minutes/week of moderate to vigorous inten-
sity aerobic exercise would induce stronger changes in
proposed breast cancer biomarker levels than would
150 minutes/week, the minimum weekly volume that is
currently recommended for cancer prevention. Our spe-
cific hypotheses were that the higher volume exercise
intervention would decrease adiposity levels (body mass
index (BMI) (weight (kg)/height (m2)), percent body fat,
subcutaneous and intra-abdominal fat) and circulating
levels of endogenous estrogens (estradiol, estrone, SHBG),
insulin resistance indicators (insulin, glucose, leptin, adi-
ponectin), and inflammatory markers (TNF-α, IL-6, high
sensitivity CRP) in a dose–response manner compared
to the moderate volume exercise intervention. Secondary
aims were to evaluate the impact of the intervention on
quality of life, perceived stress, happiness, satisfaction with
life, sleep quality, exercise adherence, and exercise mainten-
ance 12 months after study completion, and to identify pre-
dictors of exercise maintenance. Although we [23,42,43]
and others [44-46] have assessed these secondary outcomes
in previous exercise trials, very few [41,47] were designed
to identify dose–response effects. In addition, we aimed to
evaluate the long-term benefit of a higher volume exercise
intervention on proposed biomarkers for breast cancer
12 months after study completion. The primary intent of
the BETA Trial is to determine whether a higher volume
of aerobic exercise is likely to provide further reductions
in breast cancer risk compared to the current moderate
volume recommendations. Such information will inform
public health guidelines addressing how to lower post-
menopausal breast cancer risk through physical activity.
Methods
Trial overview
The BETA Trial is a two-centered, two-armed randomized
control exercise intervention trial conducted in Calgary
and Edmonton, Alberta, Canada between June, 2010 and
June 2014 that included 400 participants. The study proto-
col was approved by the Alberta Cancer Research Ethics
Committee and the Conjoint Health Research EthicsBoard of the University of Calgary and the Health
Research Ethics Board of the University of Alberta. All
participants provided written informed consent. The ori-
ginal study consisted of a year-long intervention with full
assessments made at baseline and 12 months. Additional
funding was obtained, after the project was initiated, that
permitted the expansion of the study to another set of
study outcome assessments at 24 months. An overview of
participant flow through the study is provided in Figure 1.
Participants
Several eligibility criteria were used to select the study
population, assessed before and after the information
session (Table 1). Women were deemed eligible for this
trial if they: were 50–74 years of age; postmenopausal; had
no previous cancer diagnosis (except for non-melanoma
skin cancer) or other major co-morbid condition (e.g. dia-
betes, cardiovascular disease, arthritis, emphysema) or had
recently undergone major reconstructive surgery; were
sufficiently physically fit to be able to participate in the ex-
ercise program and able to maintain acceptable heart and
lung function during a sub-maximal treadmill test; BMI
between 22 and 40; moderately inactive as determined by
the baseline physical activity and fitness assessments;
had no external factors influencing estrogen metabol-
ism, i.e., were non-users of exogenous hormones or drugs
related to estrogen metabolism and breast tissue growth;
were non-smokers; did not consume more than two drinks
of alcohol/day; were English-speaking and able to complete
questionnaires and follow instructions in English; were res-
idents of Calgary or Edmonton and able to attend the fit-
ness facility regularly; were not intending to be away for
more than four weeks consecutively and eight weeks in
total during the year of intervention; and were not cur-
rently on a weight loss program or planning to start one.
A number of strategies were used to recruit partici-
pants for this study. The primary method of recruitment
was through the Calgary and Edmonton centers of Screen
Test, the Alberta Breast Cancer Screening Program. This
method was chosen because it provided access to an ap-
propriate study population that is similar in education and
ethnicity to women of the same age in the general Alberta
population and had been used successfully previously
in the ALPHA Trial [20]. All women in the Screen Test
database who were between the ages of 50–74, living in
Calgary and Edmonton and had attended Screen Test for a
mammogram within the previous two years, from 2008 to
2010, were sent letters of invitation directly from the
Screen Test Chief Radiologist. Using Screen Test was ad-
vantageous because the invitation was endorsed by an au-
thorized custodian of their information and came from an
organization in which they already had an established rela-
tionship. These letters of invitation were followed up with
individual phone calls to determine eligibility and to invite
Telephone-administered Participant 
Eligibility Questionnaire (PEQ) 
Aerobic exercise @300 
minutes/week 
Information Session; Informed consent; 
Baseline Questionnaires  
Doctor’s permission for unrestricted 
physical activity  
Blood sample and screening for chronic 
disease
Fitness exam and anthropometric 
measurements 
Adiposity assessments by CT scan and 
DXA scan 
Randomization 
Aerobic exercise @150 
minutes/week 
12-month Assessments 12-month Assessments 
24-month Assessments 24-month Assessments 
Figure 1 Participant flow chart for the BETA Trial, Alberta, Canada.
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phone calls were made to each selected Screen Test par-
ticipant. Additional participant recruitment was done
through media campaigns conducted in both cities twice
during the trial. These media campaigns were very suc-
cessful and resulted in a large response. Finally, recruit-
ment was also done in collaboration with physicians who
are members of the Alberta Family Physicians Research
Practice Network and who agreed to display study mate-
rials in their offices and clinics. Brochures and posters
were distributed to 90 family physicians in Calgary and
Edmonton with information on the study and links to a
study website specially designed for this project.
All women who were invited or who contacted our study
centers underwent preliminary screening for eligibility(using the Participant Eligibility Questionnaire; see Table 1)
by telephone. Women who remained eligible and inter-
ested were invited to attend an information session at
either the Tom Baker Cancer Center in Calgary or the
University of Alberta in Edmonton. At the information
session, the study rationale, methods, intervention and
follow-up were explained in detail and the roles and re-
sponsibilities of the study participants clearly outlined. If
these women remained interested in the study, informed
consent was obtained and baseline questionnaires were
completed at the information session.
The locations of study assessments were as follows.
Health-related fitness assessments for Edmonton partici-
pants took place at the Cross Cancer Institute and the
Behavioral Medicine Fitness Center at the University of
Table 1 Participant eligibility criteria and assessment methods in the BETA Trial, Alberta, Canada
Reason for criterion Assessment methods Timing of assessment
Appropriate target group for breast cancer risk reduction
Female Screen Test1 database Before contacting participant/
immediately upon contact
Age 50–74 years at baseline Screen Test database or PEQ2 Before contacting participant
Postmenopausal PEQ After participant indicates interest
No previous breast cancer diagnosis PEQ After participant indicates interest
Fit to undertake exercise program
No major co-morbidities Screening questionnaires and blood tests After participant indicates interest
No previous invasive cancer PEQ After participant indicates interest
Passes the self-completed Physical Activity Readiness
Questionnaire
PEQ After participant indicates interest
Obtains physician approval to participate PARmed-X3; approval to do 60 minutes of
aerobic exercise (“unrestricted physical
activity – start slowly and build up gradually”)
five times/week for 12 months
After Information Session
Acceptably healthy heart and lung function during fitness test Sub-maximal treadmill test After blood sample and obtaining
physician approval
Risk profile amenable to change with exercise intervention
Body mass index 22.0-40.0 PEQ (screening) and objective measurement
of height and weight
After participant indicates interest
(PEQ) and after exercise tester
approval (height and weight)
Moderately sedentary lifestyle (no more than 3 days/week
of moderate-intensity recreational activity lasting a maximum
of <30 minutes/session). Or, no more than 120 minutes
of moderate-intensity recreational activity/week.
PEQ (screening) and PYTPAQ4
(comprehensive)
After participant indicates interest
(PEQ) and at Information Session
(PYTPAQ)
Estimated VO2max ≤ 34.5 mL/kg/min. If VO2max was between
34.6 and 37.0 mL/kg/min, accelerometer count <10,000
steps/day over seven days.
Sub-maximal treadmill test; seven-day
accelerometry (Actigraph GT3Xplus®) if
VO2max 34.6-37.0 mL/kg/min
After physician approval
No other outside factors to influence estrogen metabolism
Not currently, previously (<6 months) or planning to take drugs
related to estrogen metabolism or breast tissue growth
PEQ After participant indicates interest
Not a current smoker, or excessive drinker PEQ After participant indicates interest
Smoker = needs to have quit for at least 6 months
Drinking maximum= no more than 14 drinks/week
Not currently or planning to undertake a weight control/loss
program or taking weight loss medications
PEQ After participant indicates interest
Logistics
Lives in Calgary or Edmonton Screen Test database and PEQ Before contacting participant and
after participant indicates interest
English-speaking Initial contact with participant and PEQ After participant indicates interest
(telephone recruiters will ascertain)
Not planning to be out of Calgary/Edmonton area more than 4
consecutive weeks during the subsequent 18 months or more
than 8 weeks during the entire year.
PEQ After participant indicates interest
1Screen Test: The Alberta Breast Screening Program.
2PEQ: Participant Eligibility Questionnaire.
3PAR-medX: Physical Activity Readiness Medical Examination.
4PYTPAQ: Past Year Total Physical Activity Questionnaire [51].
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Baker Cancer Center and at the Faculty of Kinesiology,
University of Calgary. Full body dual energy X-ray absorp-
tiometry (DXA) scans were taken for Calgary participantsat the Human Performance Laboratory, Faculty of Kinesiology,
University of Calgary and for Edmonton participants at
the Human Nutrition Centre, University of Alberta. Com-
puted tomography (CT) scans were taken at the Foothills
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Institute in Edmonton. Supervised exercise sessions took
place at the Westside Recreation Centre in Calgary and
the Behavioural Medicine Fitness Centre at the University
of Alberta in Edmonton.
Randomization
Randomization was stratified by study centre (Edmonton
or Calgary) and baseline BMI (< or ≥30) to ensure bal-
ance between the two arms with respect to study sites
(i.e., potential differences in the participant populations)
and the proportion of obese participants. Blocking was
used within strata with blocks of four or six to ensure bal-
ance between the two arms with respect to the number of
participants. The use of different blocks sizes that we ran-
domly permuted made it harder to predict the sequence
that was up-coming. The random allocation sequence was
generated by user-defined functions in R software (version
2.11). The allocations were concealed in numbered enve-
lopes prepared by a staff member unrelated to the study
team. Randomization was performed only for women who
were eligible for the study and had completed all baseline
measurements (Figure 1). Each participant was randomly
assigned to either the HIGH volume (300 minutes/week)
aerobic exercise intervention group or to the MODERATE
volume (150 minutes/week) aerobic exercise control group.
Participants and exercise trainers, by necessity, were
unblinded to the intervention assignment.
Interventions
The two exercise groups were determined by doubling
the duration of each exercise session for the HIGH versus
MODERATE group. Both groups completed the same
frequency (five days/week) and intensity (moderate-to-
vigorous) of aerobic exercise. The targets were 60 minutes/
session, totaling 300 minutes/week for the HIGH group,
and 30 minutes/session, totaling 150 minutes/week for
the MODERATE group (Table 2). The volume of 150 minutes/
week, the minimum amount recommended for cancer
prevention, was based on Health Canada’s Guidelines for
aerobic activity [15,16] and physical activity guidelines
from the American Cancer Society [14,48]. The HIGH
group was assigned 300 minutes/week to double the
MODERATE prescription. Both groups participated in a
structured exercise program consisting of three supervised
and two unsupervised sessions/week. Polar® FT4 heart rate
monitors (©Polar Electro, Canada) were given to each par-
ticipant and used to ensure a 65-75% maximum heart rate
reserve (HRR) was being achieved during each exercise
session. The percentage of HRR was chosen because true
VO2 maximum values were not obtained during the base-
line fitness testing, only sub-maximal VO2 values. Heart
rate reserve, the next most suitable measure, is equivalent
to VO2 reserve and can be used in exercise prescriptions[49]. The frequency, intensity and duration of exercise
were gradually increased during the first three months of
the intervention until the target exercise prescriptions
were attained (Table 2). This ramp-up period was imple-
mented to reduce the risk of injury and familiarize the
previously inactive participants to frequent exercise. Once
full prescription was reached, participants were closely
monitored through scheduled appointments and direct
supervision by a team of exercise trainers to ensure targets
were being maintained.
Any kind of aerobic activity that raised the participants’
heart rate into their target zone was allowed as part of this
exercise intervention. All exercise sessions were recorded
by the exercise trainers on weekly exercise logs. For each
session, participants reported the date, type of aerobic activ-
ities, total exercise time, total amount of time spent in their
target heart rate zone, average heart rate as well as their
rate of perceived exertion during the session. Beginning at
week 5 of the intervention, participants were required to in-
corporate home-based or unsupervised exercise sessions.
For home-based sessions participants recorded their activ-
ities in journals that were provided. Unsupervised sessions
were also recorded and saved by the participants’ heart rate
monitors and documented by an exercise trainer at the next
supervised session in weekly exercise logs.
In addition, an educational manual developed by our
exercise trainers, who are trained exercise physiologists,
was created specifically for this study. The manual in-
cluded 52 weeks of tips on how to start and maintain an
exercise program. Several topics were covered ranging
from how to choose appropriate clothing for exercise,
how to use the aerobic exercise equipment and avoid in-
jury, and on maintaining interest and enthusiasm in the
exercise program. The manual was provided to each study
participant during the first exercise session. During that
session, the exercise trainer reviewed all of the material in
the manual one-on-one with each participant. The exer-
cise program was then individualized to the age, fitness
level, interests of each participant. The exercise trainers
closely monitored the participants during the first weeks
of the exercise intervention to ensure that the participants
were able to manage the increased frequency, duration
and intensity of the intervention over the three month
ramp-up period. They also re-assessed their fitness levels
every three months in order to adjust the exercise pre-
scription to ensure that the study participants were con-
tinually able to improve their level of energy expenditure
at each session.
Methods to improve study adherence
The exercise intervention was based on the Theory of
Planned Behavior [50], which is a motivational theory of
human behavior. Various behavior change techniques were
incorporated into the intervention to increase intentions to
Table 2 Year-long exercise intervention protocol for

















1 3 0 50-60 15 – 20 10 – 15
2 3 0 50-60 15 – 20 10 – 15
3 3 0 55-65 20 – 25 15 – 20
4 3 0 55-65 20 – 25 15 – 20
5 3 1 60-70 25 – 30 15 – 20
6 3 1 60-70 30 – 35 20 – 25
7 3 1 60-70 35 – 40 20 – 25
8 3 1 60-70 40 – 45 20 – 25
9 3 2 60-70 45 – 50 25 – 30
10 3 2 65-75 50 – 55 25 – 30
11 3 2 65-75 55 – 60 25 – 30
12 3 2 65-75 60 30
13-52 3 2 65-75 60 30
1% HRR: percentage of calculated heart rate reserve.
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ning for exercise (i.e., detailed plans for the exercise
program), instrumental attitudes (i.e., anticipated benefits
of the exercise program), affective attitudes (i.e., antici-
pated enjoyment of the exercise program), injunctive
norm (i.e., perceived approval and social support for the
exercise program), descriptive norm (i.e., perceived role
modeling of the exercise program), and perceived behav-
ioral control (i.e., perceived controllability and self-efficacy
for doing the exercise program).
Start Up package, incentives and feedback
Since the participants were inactive when they enrolled in
the study, a start up package with various items needed to
begin a regular exercise program was provided to each
participant. The package included: a voucher for a new
pair of running shoes, a water bottle, an athletic t-shirt
and a journal to document their weekly activities and
progress. Other incentives, such as gift certificates (ob-
tained through donations), were given to participants as
they reached various milestones throughout the trial. Par-
ticipants were provided with continuous feedback on
their progress from the exercise trainers and were given a
summary and explanation of results from all fitness and
anthropometric assessments that were taken at the begin-
ning and end of the study.
Educational and group sessions
The exercise trainers facilitated monthly hour-long
group exercise sessions for participants. These sessionswere an opportunity for participants to learn new aer-
obic activities and interact with other participants. Edu-
cational sessions also instructed participants on various
topics related to overall health and wellness, e.g., injury
prevention, learn to run, stretching and flexibility. Ses-
sions were not mandatory but participants were encour-
aged to attend.
Adherence challenges
Adherence challenges were used to improve compliance
during periods when attendance was expected to be lower
than normal, such as the summer months and winter holi-
days. During these challenges, participants with perfect or
near perfect compliance were eligible to win various prizes
e.g., gift certificates, donations from local merchants, to
acknowledge their commitment to the study.
Parking expenses
To ensure participants did not incur additional expenses
while participating in the study, any parking costs associ-
ated with study-related appointments were reimbursed.
Vacation planning
Our exercise trainers met with the participants before
planned vacations and completed a Vacation Planning
Form that included strategies for maintaining exercise
whilst away. Since each participant had her own heart
rate monitor, they were asked to continue wearing the
monitor and maintaining their weekly exercise logs for
the duration of their vacation. These materials were
returned to study staff at the end of the vacation.
Absences and illness
Participants were expected to plan their weekly supervised
sessions and to book these with our exercise trainers who
followed up by telephone and email with any participants
who missed their supervised sessions. Reasons for ab-
sences were recorded and a central communication book
was maintained so that all exercise trainers knew the sta-
tus of each participant at all times. If a participant was ill
and unable to exercise, the exercise trainers worked with
them individually to help them resume their exercise
program once they returned to regular sessions.
Newsletters and website
To maintain contact with our study participants, we cre-
ated a quarterly newsletter that was mailed or emailed
to all participants directly. It included updates on the
study progress, profiles of study participants from each
center, study staff profiles, as well as general articles on
health topics. We also created and maintained an active
study website (www.beta-trial.com) that was used exten-
sively for communication and information dissemination
with the study participants. Finally, we produced a
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that was professionally printed and distributed as a gift
and souvenir of the research study to all the participants.
Collectively, all of these activities increased the sense of
attachment and interest in the study.
Social events
To maintain engagement and permit social interaction
between the participants, exercise trainers and study
staff, several social events were organized that included
two formal events held at the universities in each centre,
as well as events either at the recreational centre or an-
other location off-site. These events included presenta-
tions from the study principal investigators on the study
progress and from the exercise trainers on tips for main-
taining motivation and interest. In addition, some events
included guest speakers, booths by local cancer charities
and fitness companies, door prizes, activities to increase
awareness and contact between participants as well as
fundraisers for local cancer charities. Teams of study
participants were also created who trained together and
walked in fundraising events for these cancer charities.
When all women had completed the 12-month interven-
tion in June 2013, wrap up events were held in each centre
to provide an overview of the study for all participants and
to encourage them to maintain their current activity levels.
Participants who achieved 100% adherence throughout the
trial were also recognized at these events.
Post-intervention resistance exercise training
The exercise intervention in the BETA Trial was restricted
to aerobic exercise only. In response to the expressed inter-
ests of our study participants, we developed a short one-
day resistance exercise training educational session with
accompanying reading materials. Once the participants
had completed all of their 12-month tests and assessments,
they were free to attend one of these sessions led by one of
our exercise trainers in each center. The purpose was to
introduce the main principles and components of resist-
ance exercise training. There was no requirement to attend
and no additional follow-up provided.
Data collection and measurements
A complete data collection schedule is provided in Table 3.
All assessments, except the PARmed-X and baseline health
questionnaire, were completed in the baseline phase, at the
end of the 12-month exercise intervention, and again at
24 months to assess exercise maintenance.
Questionnaires
Baseline health Baseline health characteristics and other
demographic information were collected through a self-
administered questionnaire that we developed and used
previously. Questions were asked regarding maritalstatus, education, employment as well as medical, men-
strual and reproductive history. Additional questions ad-
dressed history of vitamin, medication and exogenous
hormone use.
Physical activity and sedentary behavior Physical
activity in the previous 12 months was self-reported at
baseline and at 12 and 24 months post-randomization
using the Past Year Total Physical Activity Questionnaire
(PYTPAQ) [51]. This questionnaire, developed by our study
team, measures all types of occupational, household and
recreational physical activity and transportation to perform
work as well as the duration, frequency and intensity of
these activities. The questionnaire has been shown to have
acceptable reliability and validity [51]. All reported ac-
tivities are coded and converted into MET-hours/week/
year using the Compendium of Physical Activities devel-
oped by Ainsworth and colleagues [52-54]. This measure
of total physical activity, which includes activities performed
outside the intervention, will be used to characterize our
study population.
Similarly, participants were asked at baseline and
12 months to report how much time they spent in seden-
tary activities over the past year using a sedentary behavior
questionnaire called the SIT-Q. This questionnaire was de-
veloped just prior to the BETA Trial by one of our study
investigators (BML) and has since undergone psychomet-
ric testing and shown to be a reliable and valid tool for
sedentary behaviour assessment [55]. Given that sedentary
behavior has been linked to many of the same breast can-
cer biomarkers as physical activity [56,57], we will explore
in our analyses how sedentary behaviour changes with our
exercise intervention.
Dietary habits Dietary intake for the previous 12 months
was reported at baseline and at 12 and 24 months using
the self-administered Canadian version of the US National
Cancer Institute’s Diet History Questionnaire [58]. Study
participants were asked not to change their dietary intake
during the study. Hence, we are interested in verifying if
dietary intake was changed since the primary purpose
of this study is to examine the independent effect of
physical activity on breast cancer biomarkers. In addition,
given that energy intake impacts body weight, and because
dietary composition might impact proposed biomarkers
of risk [59-62], diet will be considered as a potential con-
founder (although the randomization reduces the chances
of this) in our statistical analyses.
Blood data
A 60 mL blood sample was taken at baseline after a mini-
mum 10 hour fast and complete abstinence from exercise
and alcohol for 24 hours. From the 60 mL, 20 mL were
used for eligibility screening to assess for underlying
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Accelerometry x2 x x x
CT Scan3 x x x
DXA Scan4 x x x
*All baseline measurements and questionnaires were completed prior to
randomization. The exercise intervention began at baseline (time 0).
1PAR Med-X: Physical Activity Readiness Medical Examination.
2Step count data were retrieved from the accelerometer devices to assess
study eligibility for any participant with a VO2max determined to be between
34.6 and 37.0 mL/kg/min.
3CT Scan: Computed Tomography Scan.
4DXA Scan: Dual Energy X-Ray Absorptiometry Scan.
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Screening tests included a complete blood count, lipid
panel, fasting glucose, creatinine, alanine aminotransferase
and thyroid stimulating hormone. Each was required to be
within normal reference ranges for the participant to be
eligible for the study. If the woman was under 55 years of
age and had not had a bilateral oophorectomy or was
uncertain of her menopausal status, a follicle stimulating
hormone test was also done. The additional 40 mL of
blood from the baseline blood draw was saved for analysis
of endogenous sex and metabolic hormones and otherbiomarkers. At baseline, if the participant did not begin
the exercise intervention within eight weeks of the initial
blood test, a repeat 40 mL, non-screening blood draw was
required to ensure true baseline values of the various bio-
markers being examined. Additional 40 mL blood samples
were taken at six, 12 and 24 months. A complete blood
collection, processing, shipping and storage protocol was
developed for this study to ensure standardization of pro-
cedures at both collection sites. All blood samples are
stored in −86°C freezers in the Alberta Cancer Research
Biorepository in Calgary. Freezerworks® Unlimited soft-
ware (version 6.02) was used to track and manage the
location and quantity of all collected samples.
Estradiol and estrone will be measured by radioimmuno-
assay with preceding organic solvent extraction and Celite
column partition chromatography steps. The assay sensi-
tivities are 2 pg/ml and 4 pg/ml, respectively, and the inter-
assay coefficients of variation (CVs) are 9-14%. SHBG,
insulin and high sensitivity CRP will be measured by solid-
phase, two-site chemiluminescent immunometric assays
on the Immulite analyzer (Siemens Healthcare Diagnostics,
Deerfield, IL). The assay sensitivities are 1 nmol/L, 2 μIU/
ml, and 0.02 mg/dL, respectively, and the interassay CVs
are <10%. Glucose will be quantified by a standard analyt-
ical procedure using the Vitros Chemistry System. Ten
additional biomarkers (from our original study aims and
hypothesized post-study funding) will be quantified using
three different multiplex assays: the Human Adipokine
panel, the Human Circulating Cancer panel and the
Human High Sensitivity panel according to the manufac-
turer’s protocol (Millipore, St. Charles, MO, USA). The
assays will be performed at Eve Technologies (Calgary,
AB, Canada) using the Bio-Plex™ 200 system (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). The Human
Adipokine panel assesses adiponectin and resistin with
assay sensitivities ranging from 2.2-11 pg/mL, the Human
Circulating Cancer panel contains leptin, FGF2, prolactin
and VEGF with sensitivities ranging from 3.6-42.8 pg/mL,
and the Human High Sensitivity panel contains IL-4, IL-6,
IL-10 and TNF-α; with sensitivities ranging from 0.11-
1.12 pg/mL. Appropriate quality control samples will be
used to monitor the reliability of each assay. Blood
samples are batched so that each participant’s baseline, six
and 12 month samples are in the same batch and an equal
number of MODERATE and HIGH exercise volume
bloods are in the same batch. Blind duplicates are in-
cluded in and between batches to estimate coefficients of
variation. All assays will be repeated for the 24-month
blood samples. All lab personnel will be blinded to the
intervention assignment.
Health-related fitness assessments
Only participants who successfully passed the baseline
blood screening criteria were invited for health-related
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rate and blood pressure assessment, a submaximal fit-
ness test, anthropometric and body composition mea-
surements. All fitness assessments were performed by a
Canadian Society for Exercise Physiology Certified Exercise
Physiologist (CSEP:CEP®) and one assistant exercise trainer.
The same testing protocols and equipment were used at
the Edmonton and Calgary study centers and all measure-
ments were taken at baseline and at 12 and 24 months.
Resting heart rate and blood pressure Following stand-
ard procedures [63] participants were instructed to sit
quietly for five minutes before measurements were taken.
Heart rate was monitored using a Polar FT4 heart rate
monitor (©Polar Electro, Canada). Resting blood pressure
was measured using a sphygmomanometer (WelchAllyn®)
and stethoscope (3 M™ Littmann®). A blood pressure read-
ing of 144/94 mmHg or lower was required for the partici-
pant to undergo the fitness test.
Body composition/Anthropometry Anthropometric data
on standing height, weight, waist and hip circumference
were measured using standardized methods and equip-
ment at the time of the fitness tests. Waist circumference
was measured using the National Institutes of Health
protocol and hip circumference was measured using the
World Health Organization procedure with an anthropo-
metric measuring tape [64]. Full body dual energy X-ray
absorptiometry (DXA) scans were taken using a Hologic
DXA system in Calgary and a General Electric Lunar iDXA
in Edmonton to assess overall percent body fat, total lean
body mass, total fat mass and bone mineral density.
Computed tomography (CT) scans were taken at the level
of the umbilicus to measure subcutaneous and intra-
abdominal adiposity. Three single slices were taken at the
L5 vertebrae and these data were then transferred to our
study radiologist at the Cross Cancer Institute in Edmonton
who reviewed each scan individually using a software
program (Aquarius Intuition by Terarecon, Inc.) that was
used to quantify amount of subcutaneous and intra-
abdominal fat at this level of the abdomen. Because of the
high cost associated with both the DXA and CT scans, only
participants who had completed all screening stages and
considered eligible for the study were given these scans at
baseline. These assessments were repeated 12 months and
24 months later (Table 3).
Cardiorespiratory fitness All participants completed a
sub-maximal cardiorespiratory testing to assess their aer-
obic fitness and determine eligibility (Table 1; Figure 1).
The multistage, modified Balke treadmill test protocol was
used [65] in which a speed of 3.0 mph is maintained
throughout the test and the grade is gradually increased
every three minutes by 2.5% starting at 0%. The test wascompleted when the participant finished the stage in
which she reached 85% of her age predicted maximum
heart rate or reached volitional exhaustion. The partici-
pant’s predicted VO2 max was estimated using the multi-
stage model and the American College of Sports Medicine
metabolic equations for estimating maximum oxygen con-
sumption [66]. To be eligible for the BETA Trial, a mini-
mum of two stages of the test had to be completed and
estimated VO2 max had to be ≤ 34.5 mL/kg/min (Table 1).
If the estimated VO2 max was between 34.6 mL/kg/min
and 37 mL/kg/min, additional assessments of their activity
levels were needed. In these individuals additional step
count data were retrieved from the accelerometer devices
(Actigraph GT3X + ® and activPAL™) that all participants
were required to wear for seven days. If it was determined
that, on average, these participants walked <10,000 steps/
day they were eligible for the study. Any woman with an
estimated VO2max greater than 37 mL/kg/min was ineli-
gible for the study. A modified version of the fitness test
was repeated at 3, 6, and 9 months post-randomization
for external verification of reported adherence to the exer-
cise prescription and as a means to adjust the prescription.
Randomization into the study occurred after all health re-
lated fitness tests were completed including the DXA and
CT scans (Figure 1).Objective measurements of physical activity and sedentary
behaviour
An accelerometer and inclinometer were worn by partici-
pants at four time points during the trial - baseline, six, 12
and 24 months (Table 3) - to complement self-reported
physical activity and sedentary behavior in the PYTPAQ
and SIT-Q, respectively. The ActiGraph GT3X+ ® acceler-
ometer (Actigraph, LLC, Pensacola, FL) was used to assess
moderate-vigorous physical activity since the GT3X+ model
is particularly suitable for measuring upright moderate-
vigorous intensity movement. The accelerometers were
worn on the hip and recorded the duration, frequency and
intensity of movement. The activPAL™ inclinometer (PAL
Technologies Ltd, Glasgow, Scotland) was adhered to the
upper thigh area. This device measured duration and fre-
quency of time spent sitting, standing and stepping (light
ambulation), and number of postural changes. The activ-
PAL™ inclinometer is considered the most accurate device
for assessing sedentary time in adults [67]. All participants
were asked to wear both devices simultaneously for seven
days immediately after their fitness tests. As mentioned
above, the step counts on the Actigraph GT3X + ® were
also used to determine eligibility in any woman with an
estimated VO2max that was deemed potentially too high.
Additionally, they were required to record, in a daily activ-
ity log, when the devices were worn each day and which
activities they were doing when not wearing the
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activity was recorded.
Participant-reported outcomes
Participants completed self-administered questionnaires
at baseline, 12 months, and 24 months to assess quality
of life, sleep quality, perceived stress, satisfaction with life,
and happiness; psychosocial factors that have been associ-
ated with exercise in some intervention trials [23,44-46]
and observational studies [68,69] and therefore might im-
prove with increasing exercise dose. Quality of life was
measured using the RAND SF-36 [70] which includes 36
questions and uses eight subscales to assess physical and
social functioning, pain, mental health. Questions were
also asked about stress using the Perceived Stress Scale
[71] and sleep using the Pittsburgh Sleep Quality index
[72]. Happiness and satisfaction with life were assessed
using the Happiness Measure [73] and the Satisfaction
with Life Scale [74], respectively.
Determinants of physical activity
The social cognitive determinants of physical activity were
assessed at baseline, 12 months, and 24 months through
participant-administered questionnaires that followed
the standard questions based on the Theory of Planned
Behavior [50]. This theory assesses attitude, subjective
norm, perceived behavioral control, intentions and plan-
ning. At the end of the study, the participants were also
asked to complete a Participant Satisfaction Questionnaire
to assess their attitudes and barriers towards exercise.
24-month follow-Up
An earlier follow-up of ALPHA Trial participants, on
average 12 months post-study completion, demonstrated
that a high follow-up response rate was attainable; how-
ever, this follow-up was restricted to completion of one
self-administered questionnaire pertaining to exercise
maintenance. In the BETA Trial, 24-month assessments
included all questionnaires, the blood draw, fitness tests,
anthropometric and body composition assessments and
objective measures of physical activity and sedentary
behaviour.
Sample size
Sample size calculations were based on a standard two-
sample mean comparison formula using α= 0.05 (two-sided).
Taking a conservative approach, the means of 12-month
outcomes (log-transformed, with adjustment for baseline
values) were compared. Results from the ALPHA Trial
provided estimates of standard deviations and ‘yardstick’
intervention effects that might be expected. A sample size
of 150 participants/group was chosen, providing 80%
power to detect anticipated changes of 12% in insulin re-
sistance and inflammatory outcomes (leptin, insulin,adiponectin) at 12 months and 99% power to detect
changes as low as 2% in all body fat outcomes. While an
initial group size of 165 was planned, because of more
rapid recruitment than anticipated due to tremendous
participant interest in the study, we increased the sample
size to 400 per group without incurring extra resource re-
quirements. The increase in sample size created a slight
improvement in power, on average, and adequately
accounted for an anticipated 10% loss-to-follow up and
more modest exercise adherence that we postulated might
occur with the higher demands associated with the exer-
cise intervention in the HIGH volume arm of the trial.
Statistical methods
The trial analysis will follow the intention-to-treat principle,
as such all participants who were randomized (n = 400) will
be included regardless of their adherence to the study.
After initial descriptive and graphical examination of the
response measurements (with a consideration of trans-
formation), we will examine correlations among markers
within each of the hypothesized pathways that are being
examined between physical activity and breast cancer
risk. This approach will guide us to a hypothesis-driven
pathway-based evaluation of intervention effects. Specific-
ally, the correlation analysis will explore if consistent pat-
terns supportive of a simultaneous evaluation of multiple
markers in each pathway is warranted. As a formal evalu-
ation approach, we will apply the linear mixed effects
model methodology to compare the changes from the
baseline to 12-month follow-up in levels of estrogens,
markers of obesity, insulin resistance and inflammation
and also in our psychosocial outcomes of interest. The
mixed model evaluation will be considered for both indi-
vidual markers (univariate outcomes) and pathway-based
multiple markers (multivariate outcomes), of which we
propose the latter to be our primary evaluation scheme.
The analysis will be performed with and without covari-
ate adjustments, initially without any adjustment based on
the randomized design, followed by adjustment for covari-
ates in which substantial imbalances between the two
groups were observed. Rates of recruitment and adher-
ence to the intervention as well as maintenance of exercise
behaviour will be estimated and examined in association
with the study participant characteristics.
Discussion
The primary results from BETA Trial will be central for
determining if 300 minutes/week of vigorous intensity
aerobic exercise is better than 150 minutes/week for
postmenopausal breast cancer risk reduction. Further-
more, any dose–response effects that are found between
exercise dose and blood biomarker changes will help to
strengthen (or refute) current hypotheses surrounding the
biologic mechanisms underlying the association, which
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depends, first and foremost, on the quality of our study
design and data collection methods.
The design of the BETA Trial was informed in large part
from our previous experience with the ALPHA Trial in
which we found that aerobic exercise influenced several
biomarkers associated with breast cancer risk. In addition,
we noted a possible dose–response effect between increas-
ing adherence to the exercise intervention and correspond-
ing changes in biomarker levels. Since these comparisons
were made within an allocation arm of a trial, rather than
from a true randomized comparison, the BETA Trial was
necessary to confirm these dose–response effects with pre-
scribed aerobic exercise.
Based on the experience of the ALPHA Trial, we rec-
ognized that women willing to participate in an exercise
intervention trial strongly preferred being randomized to
an exercise group rather than a control group that did
no exercise. Furthermore, there was some contamination
within the control group of the ALPHA Trial with some
study participants starting an exercise and weight loss
program on their own. Amongst the control group, 53%
started exercising and 63% decreased their caloric intake
over the year based on self-report as compared to their
baseline assessments of the past 12 months. Given that
the relevant research question after the ALPHA Trial was
“what is the optimal dose of aerobic activity?” rather than
“does exercise influence these biomarkers for breast
cancer?”, we opted for a dose–response trial.
Several aspects of the BETA Trial design, including sub-
ject recruitment, data collection methods, exercise inter-
vention, sample size and analysis also derived from our
experience with the ALPHA Trial. The ALPHA Trial had
very high retention and adherence rates and provided
meaningful insights into the potential etiology between
physical activity and breast cancer risk. Hence, for the
BETA Trial, we used the same study methods with some
refinements. For example, we recognized the advantage of
media campaigns for recruitment and so used these effect-
ively once we had all protocols in place and had begun
recruitment through letters of invitation with the breast
screening program. The media campaigns provided a large
influx of possible participants all at once which demanded
an increase in study personnel to meet this recruitment
drive. In addition, we created and used a study website
more routinely to communicate with our study partici-
pants. We also enhanced our newsletters by making them
longer, with more information and articles to interest the
participants. In the ALPHA Trial, we used group sessions
offered every three to four months in addition to individ-
ual exercise sessions whereas in the BETA Trial, group
exercise sessions were offered every month. We also in-
creased the number of exercise trainers and the facilities
were open six days/week with availability 12 hours dailyfor participants to drop in. In the BETA Trial, we contin-
ued the use of several incentives plus additional incentives
to enhance adherence, e.g., adherence challenges.
A key component to the success of a multi-centered
trial, such as this one, is standardization of all study
methods across study sites. Hence, we developed stan-
dardized protocols for all of the study methods and a
lengthy manual of operations. We held weekly meetings
of all team members at both sites that included the exer-
cise testers, study staff and the two principal investigators.
In addition, our study staff and exercise testers met
throughout the study to ensure that the methods for
exercise testing, for delivering the exercise intervention,
and for collecting and managing all the data were stan-
dardized. Any changes to study procedures or protocols
that were needed were fully discussed and implemented at
both sites. Several additional factors were crucial to the
success of our study. The BETA Trial methods had been
largely developed and tested in the ALPHA Trial and
therefore we were able to learn from our successes and
build upon them to deliver an even better intervention to
a larger study population. Recruitment to the study was
greater than expected partly because of the heightened
awareness of our research activities due to previous publi-
city from the ALPHA Trial. Also retention to the study
was very high in (96%) since we implemented protocols to
follow-up our non-adherent participants and provided
participants with a number of incentives and feedback on
their progress - e.g., receiving results from their health-
related fitness and body composition measurements at 12
and 24 months - to help maintain involvement in the trial.
We had preliminary evidence from the ALPHA Trial that
previously inactive, postmenopausal women could be mo-
tivated to achieve and sustain high levels of activity and
hence used all of our previously developed approaches,
and several new incentives that were outlined above, to
achieve exercise adherence even with the HIGH volume
group. Another strength of our study was the use of rigor-
ous measurement methods for all of the assessments made,
including objective assessments of physical fitness, physical
activity, sedentary behaviour and body composition. Our
laboratory assays are being conducted in highly reputable
laboratories (of co-author FZS) employing methods that
provide accurate and reliable measurements.
The implications of the BETA Trial findings are diverse.
By prescribing a higher dose of exercise than in previous,
comparable biomarker trials [10,24,33,75,76], the BETA
Trial will reveal whether or not greater reductions in
proposed biomarkers for breast cancer are possible with
additional exercise. Furthermore, further exploration of
the mechanisms underlying biomarker changes - e.g.,
the potential benefit from exercise in the absence of
significant weight loss - will enable clearer public
health messaging for primary cancer prevention. Our
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of life, perceived stress, sleep, and happiness, could
help motivate inactive women to become physically
active after menopause. Furthermore, the BETA Trial
will inform future disease prevention initiatives by
demonstrating the ability of these women to achieve a
high volume of regular exercise over the long-term and
to maintain this level of activity independently, 12 months
beyond the intervention period. Ultimately our findings
will help to refine and strengthen the current public health
guidelines for primary breast cancer prevention, to
decrease the future incidence of breast cancer.
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